📣 VC round data is live. Check it out!
- Public Comps
- Editas Medicine
Editas Medicine Valuation Multiples
Discover revenue and EBITDA valuation multiples for Editas Medicine and similar public comparables like NervGen Pharma, Hansa Biopharma, S Biomedics, Eledon Pharmaceuticals and more.
Editas Medicine Overview
About Editas Medicine
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Founded
2013
HQ

Employees
246
Website
Financials (LTM)
EV
$166M
Valuation Multiples
Start free trialEditas Medicine Financials
Editas Medicine reported last 12-month revenue of $35M and negative EBITDA of ($141M).
In the same LTM period, Editas Medicine generated $35M in gross profit, ($141M) in EBITDA losses, and had net loss of ($144M).
Revenue (LTM)
Editas Medicine P&L
In the most recent fiscal year, Editas Medicine reported revenue of $41M and EBITDA of ($149M).
Editas Medicine is unprofitable as of last fiscal year, with EBITDA margin of (367%) and net margin of (395%).
Financial data powered by Morningstar, Inc.
Editas Medicine Stock Performance
Editas Medicine has current market cap of $295M, and enterprise value of $166M.
Market Cap Evolution
Editas Medicine's stock price is $3.01.
Editas Medicine share price increased by 0.7% in the last 30 days, and by 75.0% in the last year.
Editas Medicine has an EPS (earnings per share) of $-1.63.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $166M | $295M | 3.8% | 0.7% | 36.8% | 75.0% | $-1.63 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialEditas Medicine Valuation Multiples
Editas Medicine trades at 4.7x EV/Revenue multiple, and (1.2x) EV/EBITDA.
EV / Revenue (LTM)
Editas Medicine Financial Valuation Multiples
As of May 5, 2026, Editas Medicine has market cap of $295M and EV of $166M.
Editas Medicine has a P/E ratio of (2.1x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Editas Medicine Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Editas Medicine Margins & Growth Rates
In the most recent fiscal year, Editas Medicine reported EBITDA margin of (367%) and net margin of (395%).
Editas Medicine Margins
Editas Medicine Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Editas Medicine Operational KPIs
Editas Medicine's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.6M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Editas Medicine Competitors
Editas Medicine competitors include NervGen Pharma, Hansa Biopharma, S Biomedics, Eledon Pharmaceuticals, LENZ Therapeutics, Amarin Corp, Protara Therapeutics, Lavipharm, Greenwich LifeSciences and Vicore Pharma Holding.
Most Editas Medicine public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| — | — | (15.1x) | (13.2x) | |||
| 13.8x | 13.2x | (8.6x) | (6.3x) | |||
| 25.9x | — | (129.5x) | — | |||
| — | — | (1.9x) | — | |||
| (0.0x) | (0.0x) | 0.0x | 0.0x | |||
| (0.0x) | (0.0x) | 0.1x | 0.1x | |||
| — | — | (2.3x) | (2.1x) | |||
| 5.4x | — | 27.9x | — | |||
This data is available for Pro users. Sign up to see all Editas Medicine competitors and their valuation data. Start Free Trial | ||||||
Editas Medicine Funding History
Before going public, Editas Medicine raised $210M in total equity funding, across 3 rounds.
Editas Medicine Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Editas Medicine
| When was Editas Medicine founded? | Editas Medicine was founded in 2013. |
| Where is Editas Medicine headquartered? | Editas Medicine is headquartered in United States. |
| How many employees does Editas Medicine have? | As of today, Editas Medicine has over 246 employees. |
| Who is the CEO of Editas Medicine? | Editas Medicine's CEO is Gilmore O’Neill. |
| Is Editas Medicine publicly listed? | Yes, Editas Medicine is a public company listed on Nasdaq. |
| What is the stock symbol of Editas Medicine? | Editas Medicine trades under EDIT ticker. |
| When did Editas Medicine go public? | Editas Medicine went public in 2016. |
| Who are competitors of Editas Medicine? | Editas Medicine main competitors include NervGen Pharma, Hansa Biopharma, S Biomedics, Eledon Pharmaceuticals, LENZ Therapeutics, Amarin Corp, Protara Therapeutics, Lavipharm, Greenwich LifeSciences, Vicore Pharma Holding. |
| What is the current market cap of Editas Medicine? | Editas Medicine's current market cap is $295M. |
| What is the current revenue of Editas Medicine? | Editas Medicine's last 12 months revenue is $35M. |
| What is the current revenue growth of Editas Medicine? | Editas Medicine revenue growth (NTM/LTM) is (29%). |
| What is the current EV/Revenue multiple of Editas Medicine? | Current revenue multiple of Editas Medicine is 4.7x. |
| Is Editas Medicine profitable? | No, Editas Medicine is not profitable. |
| What is the current EBITDA of Editas Medicine? | Editas Medicine has negative EBITDA and is not profitable. |
| What is Editas Medicine's EBITDA margin? | Editas Medicine's last 12 months EBITDA margin is (402%). |
| What is the current EV/EBITDA multiple of Editas Medicine? | Current EBITDA multiple of Editas Medicine is (1.2x). |
| What is the current FCF of Editas Medicine? | Editas Medicine's last 12 months FCF is ($167M). |
| What is Editas Medicine's FCF margin? | Editas Medicine's last 12 months FCF margin is (478%). |
| What is the current EV/FCF multiple of Editas Medicine? | Current FCF multiple of Editas Medicine is (1.0x). |
| How many companies Editas Medicine has acquired to date? | Editas Medicine hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Editas Medicine has invested to date? | Editas Medicine hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Editas Medicine
Lists including Editas Medicine
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.